Full Coverage

ZymoGenetics Inc. Q1 2008 Earnings Call Transcript

                   
seekingalpha.com
May 13, 2008
        
Story Timeline:  205 days

posted on: May 13, 2008 | about stocks: ZGEN Executives Susan Specht - I will begin with the progress report on the RECOTHROM launch, then I will turn it over to our Chief Scientific Officer, Doug Williams, to discuss progress with our pipeline and then, Jim Johnson, our CFO will then briefly... [read full story]                    

Add Comment
Latest article on this story:

ZymoGenetics Announces Publication of Five IL-21 ASCO Abstracts

 redorbit.com May 16, 2008
First article on this story:

ZymoGenetics Announces Publication of Five IL-21 ASCO Abstracts

 wallstreet-online.de May 15, 2008
Selected publications with coverage of this story:
redorbit.com seekingalpha.com finanzen.net euroinvestor.co.uk wallstreet-online.de finanznachrichten.de
RELATED
Found 4 documents:
                   

ZymoGenetics Announces Publication of Five IL-21 ASCO Abstracts

redorbit.com
May 16, 2008
        

Posted on: Friday, 16 May 2008, 00:00 CDT ZymoGenetics, Inc. (NASDAQ:ZGEN) today announced that results from Interleukin 21 (IL-21) studies will be presented or published at the American Society of Clinical Oncology (ASCO) 2008 annual meeting. Renal cell cancer is the lead indication for IL-21,...

                   

ZymoGenetics Announces Publication of Five IL-21 ASCO Abstracts

finanznachrichten.de
May 16, 2008
        

ZymoGenetics, Inc. (NASDAQ:ZGEN) today announced that results from Interleukin 21 (IL-21) studies will be presented or published at the American Society of Clinical Oncology (ASCO) 2008 annual meeting. Renal cell cancer is the lead indication for IL-21, and previously, ZymoGenetics presented...

                   

ZymoGenetics Announces Publication of Five IL-21 ASCO Abstracts

finanzen.net
May 16, 2008
        

ZymoGenetics, Inc. (NASDAQ:ZGEN) today announced that results from Interleukin 21 (IL-21) studies will be presented or published at the American Society of Clinical Oncology (ASCO) 2008 annual meeting. Renal cell cancer is the lead indication for IL-21, and previously, ZymoGenetics presented...

                   

ZymoGenetics Announces Publication of Five IL-21 ASCO Abstracts

wallstreet-online.de
May 15, 2008
        

ZymoGenetics, Inc. today announced that results from Interleukin 21 (IL-21) studies will be presented or published at the American Society of Clinical Oncology (ASCO) 2008 annual meeting. Renal cell cancer is the lead indication for IL-21, and previously, ZymoGenetics presented interim results...